24/7 Market News Snapshot 21 August, 2025 – Aptorum Group Limited Class A Ordinary Shares (NASDAQ:APM)

August 21, 2025

DENVER, Colo., 21 August, 2025 (www.247marketnews.com) – (NASDAQ:APM) are discussed in this article.
Aptorum Group Limited (APM) is witnessing a significant surge in pre-market trading, currently valued at $2.171—marking an impressive increase of 70.94% from the previous session’s close of $1.270. This sharp rise is accompanied by robust trading activity, with volumes reaching 7.60 million shares, reflecting heightened investor enthusiasm. Analysts suggest that this momentum could indicate further upward movement for the stock, making it a focal point for traders in the coming sessions.

In a notable development within the biotechnology sector, DiamiR Biosciences Corp., recognized for its cutting-edge blood-based diagnostics aimed at assessing brain health, has secured regulatory approval from the New York State Department of Health (NYSDOH) for its APOE Genotyping test. This major milestone enables DiamiR to offer validated testing across various biological samples, which is crucial for risk evaluation related to cognitive decline.

The NYSDOH’s rigorous standards for laboratory-developed tests underscore the significance of this approval, assuring healthcare providers of the test’s reliability in assessing genetic predispositions and aiding personalized care strategies. Dr. Alidad Mireskandari, CEO of DiamiR, emphasized the importance of this development, highlighting that the APOE Genotyping test is pivotal not only for understanding genetic risks but also for enhancing clinical trial participation and patient management.

Additionally, the increasing risks associated with late-onset Alzheimer’s disease, particularly for individuals carrying the APOE ε4 allele, generate significant demand for such diagnostic solutions. This test complements DiamiR’s expansive range of offerings that focus on utilizing advanced microRNA analysis for brain health monitoring.

Aptorum Group’s recent strategic move to merge with DiamiR, anticipated to conclude in the fourth quarter of 2025, aims to synergize their capabilities in delivering innovative therapeutic solutions and diagnostics, positioning them advantageously within the rapidly evolving healthcare sector.

Related news for (APM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.